Cristina Hernández-Munain

Dr. Cristina Hernández-Munain

Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Spain
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
ABAxel Bouchon
Axel Bouchon
Cristina Hernández-MunainCristina Hernández-Munain
Cristina Hernández-Munain
MCMarina Cella
Marina Cella
MCMarco Colonna
Marco Colonna
Gene targeting of the adaptor molecule DAP12 in mice caused abnormal distribution and impaired antigen presentation capacity of dendritic cells (DCs). However, the DAP12-associated receptors expressed on DCs and their functions have not been identified yet. Here we show that the triggering receptor expressed on myeloid cells-2 (TREM-2) is a cell surface receptor on human monocyte-derived DCs, which is associated with DAP12. TREM-2/DAP12 promotes upregulation of CC chemokine receptor 7, partial DC maturation, and DC survival through activation of protein tyrosine kinases and extracellular signal–regulated kinase. In contrast to Toll-like receptor-mediated signaling, TREM2/DAP12 stimulation is independent of nuclear factor-κB and p38 stress-activated protein kinase. This novel DC activation pathway may regulate DC homeostasis and amplify DC responses to pathogens, explaining the phenotype observed in DAP12-deficient mice.

1 June 1999 in Immunity
Verified
Journal Article
Closed access
Cristina Hernández-MunainCristina Hernández-Munain
Cristina Hernández-Munain
BSBarry P Sleckman
Barry P Sleckman
MKMichael S Krangel
Michael S Krangel

1 February 2012 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
MMMarta Montes
Marta Montes
ACAlexandre Cloutier
Alexandre Cloutier
NSNoemí Sánchez-Hernández
Noemí Sánchez-Hernández
LMLaetitia Michelle
Laetitia Michelle
BLBruno Lemieux
Bruno Lemieux
CSCarlos Suñé
Carlos Suñé
Complex functional coupling exists between transcriptional elongation and pre-mRNA alternative splicing. Pausing sites and changes in the rate of transcription by RNA polymerase II (RNAPII) may therefore have fundamental impacts in the regulation of alternative splicing. Here, we show that the elongation and splicing-related factor TCERG1 regulates alternative splicing of the apoptosis gene Bcl-x in a promoter-dependent manner. TCERG1 promotes the splicing of the short isoform of Bcl-x (Bcl-xs) through the SB1 regulatory element located in the first half of exon 2. Consistent with these results, we show that TCERG1 associates with the Bcl-x pre-mRNA. A transcription profile analysis revealed that the RNA sequences required for the effect of TCERG1 on Bcl-x alternative splicing coincide with a putative polymerase pause site. Furthermore, TCERG1 modifies the impact of a slow polymerase on Bcl-x alternative splicing. In support of a role for an elongation mechanism in the transcriptional control of Bcl-x alternative splicing, we found that TCERG1 modifies the amount of pre-mRNAs generated at distal regions of the endogenous Bcl-x. Most importantly, TCERG1 affects the rate of RNAPII transcription of endogenous human Bcl-x. We propose that TCERG1 modulates the elongation rate of RNAPII to relieve pausing, thereby activating the proapoptotic Bcl-xS 5′ splice site.

1 June 1998 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
Cristina Hernández-MunainCristina Hernández-Munain
Cristina Hernández-Munain
JRJoseph L. Roberts
Joseph L. Roberts
MKMichael S. Krangel
Michael S. Krangel
To understand the molecular basis for the dramatic functional synergy between transcription factors that bind to the minimal T-cell receptor α enhancer (Eα), we analyzed enhancer occupancy in thymocytes of transgenic mice in vivo by genomic footprinting. We found that the formation of a multiprotein complex on this enhancer in vivo results from the occupancy of previously identified sites for CREB/ATF, TCF/LEF, CBF/PEBP2, and Ets factors as well as from the occupancy of two new sites 5′ of the CRE site, GC-I (which binds Sp1 in vitro) and GC-II. Significantly, although all sites are occupied on a wild-type Eα, all sites are unoccupied on versions of Eα with mutations in the TCF/LEF or Ets sites. Previous in vitro experiments demonstrated hierarchical enhancer occupancy with independent binding of LEF-1 and CREB. Our data indicate that the formation of a multiprotein complex on the enhancer in vivo is highly cooperative and that no single Eα binding factor can access chromatin in vivo to play a unique initiating role in its assembly. Rather, the simultaneous availability of multiple enhancer binding proteins is required for chromatin disruption and stable binding site occupancy as well as the activation of transcription and V(D)J recombination.

1 October 1998 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
MKMichael S. Krangel
Michael S. Krangel
Cristina Hernández-MunainCristina Hernández-Munain
Cristina Hernández-Munain
PLPilar Lauzurica
Pilar Lauzurica
MMMichelle McMurry
Michelle McMurry
JRJoseph L. Roberts
Joseph L. Roberts
XZXiao‐Ping Zhong
Xiao‐Ping Zhong

15 December 2000 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
HAHydar Ali
Hydar Ali
JAJasimuddin Ahamed
Jasimuddin Ahamed
Cristina Hernández-MunainCristina Hernández-Munain
Cristina Hernández-Munain
JBJonathan L. Baron
Jonathan L. Baron
MKMichael S. Krangel
Michael S. Krangel
DPDhavalkumar D. Patel
Dhavalkumar D. Patel
Chemoattractants are thought to be the first mediators generated at sites of bacterial infection. We hypothesized that signaling through G protein-coupled chemoattractant receptors may stimulate cytokine production. To test this hypothesis, a human mast cell line (HMC-1) that normally expresses receptors for complement components C3a and C5a at low levels was stably transfected to express physiologic levels of fMLP receptors. We found that fMLP, but not C3a or C5a, induced macrophage inflammatory protein (MIP)-1β (CCL4) and monocyte chemoattractant protein-1 (CCL2) mRNA and protein. Although fMLP stimulated both sustained Ca2+ mobilization and phosphorylation of extracellular signal-regulated kinase (ERK), these responses to C3a or C5a were transient. However, transient expression of C3a receptors in HMC-1 cells rendered the cells responsive to C3a for sustained Ca2+ mobilization and MIP-1β production. The fMLP-induced chemokine production was blocked by pertussis toxin, PD98059, and cyclosporin A, which respectively inhibit Giα activation, mitgen-activated protein kinase kinase-mediated ERK phosphorylation, and calcineurin-mediated activation of NFAT. Furthermore, fMLP, but not C5a, stimulated NFAT activation in HMC-1 cells. These data indicate that chemoattractant receptors induce chemokine production in HMC-1 cells with a selectivity that depends on the level of receptor expression, the length of their signaling time, and the synergistic interaction of multiple signaling pathways, including extracellular signal-regulated kinase phosphorylation, sustained Ca2+ mobilization and NFAT activation.